Fig. 6: Raf-1 regulates TRIM22-induced GBM cell proliferation in vivo and in vitro.
a Luciferase activity of U251MG and A172 cells transfected with Flag-TRIM22 and Raf-1S338A, along with a reporter plasmid carrying the ERK1/2 promoter relative to the negative control (n = 3 per group). U251MG: Finteraction(3, 16) = 75.25, P < 0.0001; A172: Finteraction(3, 16) = 145.6, P < 0.0001. b Growth curves generated using cell counting data over 72 h for the indicated cells (n = 3 per group). U251MG: Finteraction(12, 40) = 5.665, P < 0.0001; A172: Finteraction(12, 40) = 16.35, P < 0.0001. c Representative images and quantification of Ki-67 immunofluorescence staining from modified U251MG and A172 cells (n = 20 per group). Scale bar: 50 μm. Blue: DAPI. U251MG [F (3, 76) = 91.93, P < 0.0001] and A172 cells [F (3, 76) = 80.77, P < 0.0001]. d Representative images and quantification of in vivo imaging (n = 5 mice per group). A172: Finteraction(6, 48) = 21.26, P < 0.0001; P1: Finteraction(6, 48) = 23.33, P < 0.0001. e Kaplan–Meier survival analysis and log-rank test performed with survival data from the indicated groups (n = 10 mice per group). A172: Log-rank (Mantel‒Cox) test, Chi square = 42.80, df = 3, P < 0.0001; P1: Log-rank (Mantel‒Cox) test, Chi square = 55.71, df = 3, P < 0.0001. The data were analyzed using one-way ANOVA (c) or two-way ANOVA (a, b and d), and all data are expressed as the mean ± standard deviation. *P < 0.05 indicates a statistically significant difference between the two groups. ns, not significant. Each experiment was repeated three times.
